Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
A6NNN8
UPID:
S38A8_HUMAN
Alternative names:
Solute carrier family 38 member 8
Alternative UPACC:
A6NNN8
Background:
The Putative sodium-coupled neutral amino acid transporter 8, also known as Solute carrier family 38 member 8, plays a crucial role in the transport of amino acids across cell membranes. This protein operates as a sodium-dependent amino acid/proton antiporter, essential for maintaining amino acid balance within cells.
Therapeutic significance:
Given its involvement in Foveal hypoplasia 2, a condition characterized by developmental defects of the eye, understanding the role of Putative sodium-coupled neutral amino acid transporter 8 could open doors to potential therapeutic strategies. This insight offers a promising avenue for addressing visual impairments associated with this condition.